Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 5 and last traded at GBX 5.42, with a volume of 45843 shares. The stock had previously closed at GBX 5.60.
Allergy Therapeutics Trading Down 0.7%
The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The business’s 50 day simple moving average is GBX 5.94 and its 200 day simple moving average is GBX 8.54. The stock has a market cap of £329.99 million, a P/E ratio of -5.37, a PEG ratio of -30.70 and a beta of 0.83.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
